Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study

References

• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988. doi:10.1161/01.str.22.8.983
   PubMed Web of Science ®Google Scholar
• Chao T-F, Lip GYH, Lin Y-J, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost. 2018;118(04):768–777. doi:10.1055/s-0038-1636534
   PubMedGoogle Scholar
• Petty GW, Khandheria BK, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Predictors of cerebrovascular events and death among patients with valvular heart disease. Stroke. 2000;31(11):2628–2635. doi:10.1161/01.STR.31.11.2628
   PubMed Web of Science ®Google Scholar
• Melgaard L, Jensen M, Overvad TF, Larsen TB, Lip GYH, Nielsen PB. Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: a descriptive nationwide cohort study. Int J Clin Pract. 2020;74(10):e13589. doi:10.1111/ijcp.13589
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lip GYH, Larsen TB, et al. Stroke prevention strategies in atrial fibrillation and heart valve abnormalities: perceptions of ‘valvular’ atrial fibrillation: results of the European heart rhythm association survey. EP Eur. 2016;18(10):1593–1598. doi:10.1093/europace/euw302
   PubMed Web of Science ®Google Scholar
• Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of valvular and non-valvular atrial fibrillation: results of a physicians’ survey. EP Eur. 2014;16(12):1720–1725. doi:10.1093/europace/euu178
   PubMed Web of Science ®Google Scholar
• Lip GYH, Collet JP, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European society of cardiology working group on thrombosis, endorsed by the ESC working. EP Eur. 2017;19(11):1757–1758. doi:10.1093/europace/eux240
   PubMed Web of Science ®Google Scholar
• Bisson A, Bodin A, Clementy N, et al. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. Int J Cardiol. 2018;260:93–98. doi:10.1016/j.ijcard.2018.03.017
   PubMed Web of Science ®Google Scholar
• Philippart R, Brunet-Bernard A, Clementy N, et al. Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire valley atrial fibrillation project. Eur Heart J. 2015;36(28):1822–1830. doi:10.1093/eurheartj/ehv163
   PubMed Web of Science ®Google Scholar
• He Q, Sze C-Y, Shum T-Y, et al. Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with valvular heart diseases: a meta-analysis. BMC Cardiovasc Disord. 2019;19(1):113. doi:10.1186/s12872-019-1089-0
   PubMedGoogle Scholar
• Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart. 2019;105(18):1432LP–1436 . doi:10.1136/heartjnl-2019-314767
   Web of Science ®Google Scholar
• de Souza Lima Bitar Y, Neto MG, Filho JAL, et al. Comparison of the new oral anticoagulants and warfarin in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Drugs R D. 2019;19(2):373–498. doi:10.1007/s40268-019-0274-z
   Web of Science ®Google Scholar
• Melgaard L, Overvad TF, Jensen M, et al. Effectiveness and safety of NOAC versus warfarin in patients with atrial fibrillation and aortic stenosis. J Am Heart Assoc. 2021;10(23):e022628. doi:10.1161/JAHA.121.022628
   PubMed Web of Science ®Google Scholar
• Strange JE, Sindet-Pedersen C, Staerk L, et al. All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. Eur Heart J Cardiovasc Pharmacother. 2021;7(FI1):f93–f100. doi:10.1093/ehjcvp/pvaa011
   PubMedGoogle Scholar
• Li H-J, Lin S-Y, Lin F-J, Hung C-S, Wang -C-C. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease. Curr Med Res Opin. 2021;37(4):535–542. doi:10.1080/03007995.2021.1885365
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart R. J Am Coll Cardiol. 2019;74(1):104–132. doi:10.1016/j.jacc.2019.01.011
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694. doi:10.1111/j.1538-7836.2005.01204.x
   PubMed Web of Science ®Google Scholar
• Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014;35(47):3377–3385. doi:10.1093/eurheartj/ehu305
   PubMed Web of Science ®Google Scholar
• Güzel T, Aktan A, Kılıç R, et al. Oral anticoagulant use and long-term follow-up results in patients with non-valvular atrial fibrillation in Turkey AFTER-2 study. Anatol J Cardiol. 2022;26(7):567–576. doi:10.5152/AnatolJCardiol.2022.1597
   PubMed Web of Science ®Google Scholar